Amylyx Pharmaceuticals Inc

{ "date": [ "202612", "202712", "202812", "202912", "203012" ], "revenue_estimate": [ null, 44.99, 112.37, 320.59, 548.88 ], "ebit_estimate": [ -175.88, -160.34, -106.91, 66.57, 309.96 ], "ebitda_estimate": [ -170.33, -137.84, -32.37, null, null ], "net_income_estimate": [ -166.51, -159.93, -77.14, 73.99, 296.34 ], "per_share_eps_estimate": [ -1.46, -1.3, -0.79, 0.6, 2.11 ], "eps_nri_estimate": [ -1.45, -1.35, -0.87, 0.6, 2.09 ], "dividend_estimate": [ null, null, null, null, null ], "book_value_per_share_estimate": [ null, null, null, null, null ], "pretax_income_estimate": [ -168.3, -161.8, -74.42, 47.2, 284.36 ], "operating_cash_flow_per_share_estimate": [ -1.16, -0.7, null, null, null ], "roa_estimate": [ null, null, null, null, null ], "roe_estimate": [ -64.02, -179.48, -405.25, null, null ], "gross_margin_estimate": [ 92, 84, 84, 84, 84 ], "operating_cash_flow_estimate": [ -128.25, -77.39, null, null, null ], "pettm_estimate": [ 0, 0, 0, 29.52, 8.42 ], "long_term_growth_rate_mean": 16.33, "long_term_revenue_growth_rate_mean": "0.00", "future_per_share_eps_estimate_growth": 19.03, "future_eps_nri_estimate_growth": 16.33, "future_revenue_estimate_growth": null, "future_ebit_estimate_growth": 11.07, "future_ebitda_estimate_growth": 38.53, "future_dividend_estimate_growth": null, "future_net_income_estimate_growth": 17.54, "future_pretax_income_estimate_growth": 18.4, "future_book_value_per_share_estimate_growth": null, "future_roa_estimate_growth": null, "future_roe_estimate_growth": -95.09, "future_gross_margin_estimate_growth": null, "future_operating_cash_flow_per_share_estimate_growth": null }

{ "date": [ "202606", "202609", "202612" ], "revenue_estimate": [ null, null, null ], "ebit_estimate": [ -42.61, -44.07, -45.4 ], "ebitda_estimate": [ -41.97, -42.63, -41.84 ], "net_income_estimate": [ -40.29, -41.76, -43.48 ], "per_share_eps_estimate": [ -0.37, -0.36, -0.38 ], "eps_nri_estimate": [ -0.36, -0.36, -0.37 ], "dividend_estimate": [ null, null, null ], "book_value_per_share_estimate": [ null, null, null ], "pretax_income_estimate": [ -40.94, -42.94, -44.6 ], "operating_cash_flow_per_share_estimate": [ -0.76, -0.72, 0.11 ], "roa_estimate": [ null, null, null ], "roe_estimate": [ null, null, null ], "gross_margin_estimate": [ null, null, null ], "operating_cash_flow_estimate": [ -84.03, -79.61, 12.16 ], "pettm_estimate": [ null, null, null ], "long_term_growth_rate_mean": 16.33, "long_term_revenue_growth_rate_mean": "0.00", "future_per_share_eps_estimate_growth": 19.03, "future_eps_nri_estimate_growth": 16.33, "future_revenue_estimate_growth": null, "future_ebit_estimate_growth": 11.07, "future_ebitda_estimate_growth": 38.53, "future_dividend_estimate_growth": null, "future_net_income_estimate_growth": 17.54, "future_pretax_income_estimate_growth": 18.4, "future_book_value_per_share_estimate_growth": null, "future_roa_estimate_growth": null, "future_roe_estimate_growth": -95.09, "future_gross_margin_estimate_growth": null, "future_operating_cash_flow_per_share_estimate_growth": null }